Advanced Glycation End Products Market, by Type (Non-fluorescent AGEs and Fluorescent AGEs ), by Application, by End User, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Advanced glycation end products (AGEs), also known as glycotoxins or atherogenic molecules, are the diverse group of highly oxidant compounds. AGEs are formed through a non-enzymatic reaction between reducing sugars and free amino groups of proteins, lipids, or nucleic acids. This reaction is also known as the Maillard or browning reaction. Advanced glycation end products (AGEs) are used to treat pathological conditions such as diabetes mellitus (DM), cardiovascular disease, Alzheimer's disease, cancer, and natural aging. Increasing prevalence of cardiovascular diseases (CVD) is expected to drive growth of the advanced glycation end products market. According to the American Heart Association, 2016, cardiovascular diseases account for 17.3 million deaths every year, globally, where an estimated 23.3 million people are expected to die from CVD by 2030. Such rising prevalence of chronic diseases is expected to drive the advanced glycation end products market growth over the forecast period.

Market Dynamics

Market players are focusing on research and development of advanced glycation end products in diabetic complications as advanced glycation end products (AGEs) are key factor in the development of metabolic memory in diabetic complications, which is expected to drive growth of the global advanced glycation end products market over the forecast period. According to the International Diabetes Federation (IDF), in 2017, the estimated number of 18 to 99 year old diabetic patients was around 425 million globally.

Key features of the study:

• This report provides in-depth analysis of the global advanced glycation end products market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2028), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global advanced glycation end products market based on the following parameters - company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
• Key companies covered as a part of this study include Merck KGaA, Diagnoptics Technologies B.V., Cell Biolabs, Inc., Shanghai Korain Biotech Co., Ltd, Scent-Sations, Inc., Z.I. de la Nau, and KOKEN CO., LTD. among others
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global advanced glycation end products market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global advanced glycation end products market

Detailed Segmentation:

• Global Advanced Glycation End Products Market, By Type:
  • Non-fluorescent AGEs
    • Carboxymethyl-lysine (CML)
    • Carboxyethyl-lysine (CEL)
    • Pyrraline
  • Fluorescent AGEs
    • Pentosidine
    • Methylglyoxal-lysine dimer (MOLD)
• Global Advanced Glycation End Products Market, By Application:
  • Diabetic Complications
  • Cancer
  • Bone Diseases
  • Neurodegenerative Diseases
  • Others
• Global Advanced Glycation End Products Market, By End User:
  • Hospitals
  • Specialty Clinics
  • Homecare Settings
• Global Advanced Glycation End Products Market, By Region:
  • North America
    • By Type:
    • Non-fluorescent AGEs
    • Carboxymethyl-lysine (CML)
    • Carboxyethyl-lysine (CEL)
    • Pyrraline
    • Fluorescent AGEs
    • Pentosidine
    • Methylglyoxal-lysine dimer (MOLD)
    • By Application
    • Diabetic Complications
    • Cancer
    • Bone Diseases
    • Neurodegenerative Diseases
    • Others
    • By End User:
    • Hospitals
    • Specialty Clinics
    • Homecare Settings
    • By Country:
    • U.S.
    • Canada
  • Latin America
    • By Type:
    • Non-fluorescent AGEs
    • Carboxymethyl-lysine (CML)
    • Carboxyethyl-lysine (CEL)
    • Pyrraline
    • Fluorescent AGEs
    • Pentosidine
    • Methylglyoxal-lysine dimer (MOLD)
    • By Application
    • Diabetic Complications
    • Cancer
    • Bone Diseases
    • Neurodegenerative Diseases
    • Others
    • By End User:
    • Hospitals
    • Specialty Clinics
    • Homecare Settings
    • By Country:
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • By Type:
    • Non-fluorescent AGEs
    • Carboxymethyl-lysine (CML)
    • Carboxyethyl-lysine (CEL)
    • Pyrraline
    • Fluorescent AGEs
    • Pentosidine
    • Methylglyoxal-lysine dimer (MOLD)
    • By Application
    • Diabetic Complications
    • Cancer
    • Bone Diseases
    • Neurodegenerative Diseases
    • Others
    • By End User:
    • Hospitals
    • Specialty Clinics
    • Homecare Settings
    • By Country:
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • By Type:
    • Non-fluorescent AGEs
    • Carboxymethyl-lysine (CML)
    • Carboxyethyl-lysine (CEL)
    • Pyrraline
    • Fluorescent AGEs
    • Pentosidine
    • Methylglyoxal-lysine dimer (MOLD)
    • By Application
    • Diabetic Complications
    • Cancer
    • Bone Diseases
    • Neurodegenerative Diseases
    • Others
    • By End User:
    • Hospitals
    • Specialty Clinics
    • Homecare Settings
    • By Country:
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • By Type:
    • Non-fluorescent AGEs
    • Carboxymethyl-lysine (CML)
    • Carboxyethyl-lysine (CEL)
    • Pyrraline
    • Fluorescent AGEs
    • Pentosidine
    • Methylglyoxal-lysine dimer (MOLD)
    • By Application
    • Diabetic Complications
    • Cancer
    • Bone Diseases
    • Neurodegenerative Diseases
    • Others
    • By End User:
    • Hospitals
    • Specialty Clinics
    • Homecare Settings
    • By End User:
    • Hospitals
    • Specialty Clinics
    • Homecare Settings
    • By Country:
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • By Type:
    • Non-fluorescent AGEs
    • Carboxymethyl-lysine (CML)
    • Carboxyethyl-lysine (CEL)
    • Pyrraline
    • Fluorescent AGEs
    • Pentosidine
    • Methylglyoxal-lysine dimer (MOLD)
    • By Application
    • Diabetic Complications
    • Cancer
    • Bone Diseases
    • Neurodegenerative Diseases
    • Others
    • By End User:
    • Hospitals
    • Specialty Clinics
    • Homecare Settings
    • By Country/Region:
    • South Africa
    • Central Africa
    • North Africa
• Company Profiles
  • Merck KGaA*
    • Company Overview
    • Material Portfolio
    • Financial Performance
    • Key Highlights
    • Market Strategies
  • Diagnoptics Technologies B.V
  • Cell Biolabs, Inc.
  • Shanghai Korain Biotech Co., Ltd
  • Scent-Sations, Inc.
  • Z.I. de la Nau
  • KOKEN CO., LTD.

"*" marked represents similar segmentation in other categories in the respective section.